Veritable’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Veritable’s Portfolio CELGZ Stock Details CELGZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-34	Closed	–	–	1031
2013 Q4	$0	Buy	+34	New	+$95	﹤0.01%	1044

Other funds holding CELGZ

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

WJA

Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Veritable's CELGZ Position: Q1 2014 in Review

Veritable sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q1 2014, closing a stake of 34 shares.

Veritable first reported a position in CELGZ in Q4 2013 and held it in 1 quarter. The position peaked at $0 in Q4 2013. 23 funds tracked by Wall St. Rank hold CELGZ as of Q1 2014.

Veritable reported no remaining Celgene Corporation Contingent Value Rights position as of Q1 2014 after selling out during the quarter.
Veritable sold 34 Celgene Corporation Contingent Value Rights shares in Q1 2014.
Veritable first reported a position in Celgene Corporation Contingent Value Rights in Q4 2013 and held it in 1 quarter.
Veritable's Celgene Corporation Contingent Value Rights position peaked at $0 in Q4 2013.
23 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q1 2014.

Based on Veritable's 13F filing for Q1 2014, filed 15 May 2014.